SCHEMBL248472

SCHEMBL248472

Cc1c(-c2ccccn2)nc2c(Cl)cccc2c1Nc1cccc(N2CCOCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R2 O00459 4/20 0.44
NPSR1 Q6W5P4 1/20 0.43
PIK3CA P42336 6/20 0.41
METAP1 P53582 2/20 0.40
CLK2 P49760 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CSNK2A1 P68400 1/20 0.39
STK3 Q13188 1/20 0.39
HIPK4 Q8NE63 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
PIK3CD O00329 1/20 0.38
CNR2 P34972 1/20 0.38
TGFBR1 P36897 2/20 0.38
SMO Q99835 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248664 0.90 PIK3CA (0.41) PIK3R2PIK3CACLK2GSK3AGSK3B
SCHEMBL249196 0.87 PIK3CA (0.40) PIK3R2NPSR1PIK3CAMETAP1CLK2
SCHEMBL2712660 0.82 PIK3CD (0.50) PIK3R2NPSR1PIK3CAPIK3CBPIK3CG
SCHEMBL2712984 0.81 PIK3R2 (0.49) PIK3R2NPSR1PIK3CAPIK3CBPIK3CG
SCHEMBL2713720 0.81 PIK3R2 (0.49) PIK3R2NPSR1PIK3CAPIK3CBPIK3CG
SCHEMBL246713 0.80 PIK3R2 (0.47) PIK3R2NPSR1PIK3CAPIK3CBPIK3CG
SCHEMBL246551 0.78 HTT (0.39) PIK3R2PIK3CACLK2GSK3AGSK3B
SCHEMBL248832 0.77 ATR (0.42) PIK3R2PIK3CAMAPK1PIK3CDCNR2
SCHEMBL248279 0.77 PIK3CD (0.63) PIK3CAPIK3CBPIK3CGPIK3CD
SCHEMBL2712587 0.74 PIK3CA (0.45) PIK3R2PIK3CAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3R2 88/4885NPSR1 2664/4885PIK3CA 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.